A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Synagis Russia
- Sponsors AbbVie
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Nov 2016 New trial record